Literature DB >> 11447581

Partial irradiation of the liver.

L A Dawson1, R K Ten Haken, T S Lawrence.   

Abstract

The use of three-dimensional radiotherapy (RT) and the prospective follow-up of patients for radiation-induced liver disease (RILD) have led to a more quantitative understanding of the partial organ tolerance of the liver compared with previous estimates based on clinical judgment alone. Parameters of both the Lyman normal tissue complication probability (NTCP) model and a local damage-organ injury (D-I) NTCP model have been fit to clinical data from patients who have received hepatic radiation. Based on analyses of over 180 patients, the liver exhibits a large volume effect and a low threshold volume for RILD. Mean liver dose is associated with RILD, and no cases of RILD have been reported in patients with a mean liver dose of less than 31 Gy. Most recent estimates of the partial liver tolerance to RT suggest that if less than 25% of the normal liver is treated with RT, then there may be no upper limit on dose associated with RILD. Estimates of the liver doses associated with a 5% risk of RILD for uniform irradiation of one third, two thirds, and the whole liver are 90 Gy, 47 Gy, and 31 Gy, respectively. Copyright 2001 by W.B. Saunders Company

Entities:  

Mesh:

Year:  2001        PMID: 11447581     DOI: 10.1053/srao.2001.23485

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  49 in total

1.  Safety evaluation of 32P-chromic phosphate-poly L lactic acid particles interstitially implanted into livers of Beagle dogs.

Authors:  Lu Liu; Peilin Huang; Qi Nie; Benzhong Qi; Qinghua Wu; Hailin Gao; Zexuan Yang; Daming Chen
Journal:  Cancer Biother Radiopharm       Date:  2012-02-08       Impact factor: 3.099

Review 2.  Radiotherapy for liver tumors.

Authors:  Florence K Keane; Shyam K Tanguturi; Andrew X Zhu; Laura A Dawson; Theodore S Hong
Journal:  Hepat Oncol       Date:  2015-04-20

Review 3.  Liver-Directed Radiotherapy for Hepatocellular Carcinoma.

Authors:  Florence K Keane; Jennifer Y Wo; Andrew X Zhu; Theodore S Hong
Journal:  Liver Cancer       Date:  2016-05-10       Impact factor: 11.740

Review 4.  Radiation therapy for liver tumors: ready for inclusion in guidelines?

Authors:  Shyam K Tanguturi; Jennifer Y Wo; Andrew X Zhu; Laura A Dawson; Theodore S Hong
Journal:  Oncologist       Date:  2014-07-07

5.  Therapeutic Potential of Adjuvant Stereotactic Body Radiotherapy for Gallbladder Cancer.

Authors:  Anand Mahadevan; Nergiz Dagoglu; Jennifer F Tseng; Khalid Khawaja; Amy Evenson
Journal:  Cureus       Date:  2015-08-10

6.  Efficacy of therapy for hepatocellular carcinoma with portal vein tumor thrombus: chemoembolization and stent combined with iodine-125 seed.

Authors:  Li Chuan-Xing; He Xu; Hu Bao-Shan; Li Yong; Shao Pei-Jian; Yu Xian-Yi; Luo Xiao-Ning; Lu Li-Gong
Journal:  Cancer Biol Ther       Date:  2011-11-15       Impact factor: 4.742

7.  Therapeutic effects and prognostic factors in three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma.

Authors:  De-Hua Wu; Li Liu; Long-Hua Chen
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

8.  Helical tomotherapy for single and multiple liver tumours.

Authors:  Tsair-Fwu Lee; Pei-Ju Chao; Fu-Min Fang; Te-Jen Su; Stephen W Leung; Hsuan-Chih Hsu
Journal:  Radiat Oncol       Date:  2010-06-24       Impact factor: 3.481

Review 9.  Challenge and hope in radiotherapy of hepatocellular carcinoma.

Authors:  Jinsil Seong
Journal:  Yonsei Med J       Date:  2009-10-20       Impact factor: 2.759

10.  Clinical utility of gadoxetate disodium-enhanced hepatic MRI for stereotactic body radiotherapy of hepatocellular carcinoma.

Authors:  Yuko Nakamura; Tomoki Kimura; Toru Higaki; Yukiko Honda; Daisuke Komoto; Takuji Yamagami; Makoto Iida; Yasushi Nagata; Yohji Honda; Hiroshi Aikata; Kazuaki Chayama; Kazuo Awai
Journal:  Jpn J Radiol       Date:  2015-07-31       Impact factor: 2.374

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.